menu
    • menu
    [{"orgOrder":0,"company":"Eisai","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Loxapine Succinate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eisai","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eisai \/ CNX Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ CNX Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Loxapine Succinate

    Menu

    Loxapine Succinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Eisai

    Japan arrow
    ICHH-25
    Not Confirmed

    Eisai

    Japan arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Loxapine Succinate

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved

    Sponsor : CNX Therapeutics

    Deal Size : $61.3 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Eisai Divests Rights to Loxapac and Parkinane LP to CNX Therapeutics

    Details : Through the divestment, the company has acquired the rights and will concentrate on commercializing Loxacin (loxapine succinate) for treating psychotic disorders and personality disorders.

    Product Name : Loxapac

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    April 02, 2024

    Lead Product(s) : Loxapine Succinate

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved

    Sponsor : CNX Therapeutics

    Deal Size : $61.3 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth